Home World News Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients with... World News Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients with Gastric, GEJ and Oesophageal Adenocarcinoma By Ogkologos - February 24, 2026 384 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from 5 years of follow-up of CheckMate 649 study Source RELATED ARTICLESMORE FROM AUTHOR How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research MOST POPULAR Beauty, Healing and Space January 27, 2021 New Technology System Allows Patients To Get A Mammogram And Biopsy... June 30, 2020 New on NCI’s Websites for January 2020 January 2, 2020 FDA Approves Nivolumab and Ipilimumab Combination for Advanced Kidney Cancer May 10, 2018 Load more HOT NEWS EMA Grants a Marketing Authorisation for Two Biosimilar Medicines, Bevacizumab Drug Combination Shows Promise for Rhabdomyosarcoma, but Can It Get to... Atezolizumab Plus Bevacizumab Approved to Treat Liver Cancer ESMO Congresses in March: Sarcoma and Rare Cancers Congress and European...